Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri on behalf of The EVA Study Group, Valter
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2018
Subjects:
Correction
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6195381/
https://ncbi.nlm.nih.gov/pubmed/30349655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26213
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items